Fulgent Genetics Strategy and Business Model

Executive Overview

Fulgent Genetics is a precision diagnostics company founded in 2011 and headquartered in Temple City, California. The company built its early reputation in next-generation sequencing-based genetic testing, then broadened its scope through acquisitions and internal investment into oncology testing, hematopathology, anatomic pathology, and a smaller therapeutics effort. That strategic shift matters because Fulgent’s pandemic-era COVID-19 testing revenue was unusually large but inherently temporary. Since then, management has been repositioning the company around a more durable precision-medicine model anchored in physician-ordered testing and pathology workflows.

Today, Fulgent’s main customers are physicians, hospitals, health systems, oncology practices, and payors, with revenue generated primarily through reimbursed laboratory testing and pathology services. The company’s geographic footprint is still primarily U.S.-based, and its strategy is centered on combining broad test-menu capability, laboratory scale, bioinformatics, and acquisition-driven expansion in oncology and pathology. For FY2023, the latest full-year figure publicly available in company filings as of mid-2024, Fulgent reported revenue of about $290.5 million. The key strategic question for investors and operators is no longer whether Fulgent can process high volumes of one-time testing, but whether it can turn its technology platform, cash balance, and acquired assets into a durable, multi-line precision diagnostics business.

Fulgent Genetics at a Glance

Logo
Common name	Fulgent Genetics
Full legal name	Fulgent Genetics, Inc.
Headquarters	Temple City, California, United States
Ownership	Public company; Nasdaq-listed. Founder Ming Hsieh was the largest disclosed beneficial owner in the company’s 2024 proxy materials.
Ticker	FLGT
Exchange	NASDAQ
Market Cap	$517.74M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2011; initial public offering in 2016; major COVID-19 testing expansion in 2020-2021; acquired CSI Laboratories in 2021 and Inform Diagnostics in 2022.
Industry or industries	Precision diagnostics, genetic testing, oncology diagnostics, anatomic pathology, precision medicine
Key products or services	Genetic testing, oncology molecular testing, hematopathology, anatomic pathology, laboratory services, therapeutics development
Geographic footprint	Predominantly United States, with a national customer base and laboratory operations centered in California and expanded through oncology and pathology facilities in other U.S. locations.
Business segments as officially reported	FY2023 public filings emphasized consolidated reporting; operationally, management discussions commonly distinguish core diagnostics, oncology, pathology, and therapeutics activities.
Company website	https://www.fulgentgenetics.com/

1. What Is the Strategy of Fulgent Genetics?

1. 1a. What is the winning aspiration of Fulgent Genetics?

   Fulgent Genetics’ public communications through FY2023 and early 2024 point to a clear post-pandemic aspiration: build a broader precision medicine company with durable revenue streams in genetic testing, oncology diagnostics, pathology, and related services. In practical terms, “winning” for Fulgent no longer means maximizing one-off pandemic testing volume. It means replacing temporary COVID-era revenue with more recurring physician-ordered and institutionally embedded testing activity, while using the balance sheet strength created during 2020-2021 to expand capabilities and improve long-term mix. The company has offered annual guidance from time to time, but it has not publicly anchored its strategy to a single long-range revenue or margin target. The more durable aspiration appears to be mix quality, customer stickiness, and capital deployment discipline.

2. 1b. Where does Fulgent Genetics play?

   Fulgent Genetics plays in specialized diagnostics rather than in routine high-volume clinical chemistry. Its chosen fields are physician-ordered genetic testing, oncology molecular diagnostics, hematopathology, anatomic pathology, and selected biopharma and therapeutics activities. Geographically, the company is primarily U.S.-focused, and commercially it plays where reimbursement, clinical complexity, and turnaround time matter: hospitals, health systems, specialty physicians, oncology practices, pathology workflows, and certain biopharma programs. This is a narrower and more defensible field than trying to compete head-on across the entire routine lab market.

3. 1c. How does Fulgent Genetics plan to win?

   Fulgent Genetics appears to plan to win through a combination of breadth, flexibility, and workflow integration. Historically, the company differentiated itself with a broad and configurable genetic test menu supported by its own technology and bioinformatics platform. More recently, it has tried to strengthen that position by adding oncology and pathology capabilities through acquisition, so that it can participate in more of the diagnostic workflow rather than only performing stand-alone molecular tests. The company’s strong cash position has also been part of the strategy: it gives Fulgent more freedom than many peers to invest, acquire, and repurchase shares while the business mix resets. In short, the intended formula is not pure low cost and not pure premium branding; it is specialized service, broad menu capability, operational flexibility, and a fuller precision-diagnostics offering.

4. 1d. What capabilities must Fulgent Genetics have in place?

   To make that strategy work, Fulgent needs strong capabilities in laboratory operations, assay development, bioinformatics, variant interpretation, pathology workflow management, reimbursement and collections, and quality compliance under laboratory regulations. It also needs commercial capabilities that are different from its earlier business mix: deeper health-system selling, oncology account management, physician education, and post-acquisition integration. Because the company is now more diversified, it also needs to coordinate molecular testing, tissue-based pathology, and reporting across multiple business lines in a way that is clinically coherent for customers.

5. 1e. What management systems does Fulgent Genetics require?

   Execution depends on rigorous laboratory quality systems, test validation processes, turnaround-time management, specimen tracking, billing discipline, and capital allocation controls. For Fulgent, the management systems that matter most are not abstract corporate scorecards; they are operational controls around chain of custody, report accuracy, reimbursement yield, denial management, and productivity per sample. The company also needs integration governance for acquired businesses, because pathology and oncology assets only create strategic value if they are commercially connected and operationally compatible. Given the company’s cash resources, an additional management system is capital allocation discipline: deciding how much to commit to internal growth, M&A, therapeutics, and buybacks.

2. What Are the Current Strategic Initiatives of Fulgent Genetics?

Based on Fulgent Genetics’ FY2023 annual reporting, investor materials, and management commentary through early 2024, the company’s current strategic agenda appears to center on six concrete initiatives.

• Rebuild the business around non-COVID revenue. The central strategic task since 2022 has been replacing pandemic testing revenue with a more durable mix of core diagnostics, oncology testing, and pathology services.
• Scale oncology and pathology. The acquisitions of CSI Laboratories and Inform Diagnostics expanded Fulgent into cancer diagnostics and anatomic pathology. Management has emphasized growing these assets and using them to deepen relationships with oncologists, hospitals, and health systems.
• Cross-sell across the platform. The strategic logic of combining molecular testing, hematopathology, and anatomic pathology is that more of the diagnostic workflow can be served within one broader platform. That should improve customer stickiness if executed well.
• Expand core genetic testing in attractive specialties. Fulgent continues to emphasize hereditary disease, reproductive health, rare disease, and oncology-related testing categories where clinical complexity and menu breadth can matter more than simple scale.
• Align the cost structure with the new revenue base. After the unwind of COVID-19 testing, cost discipline became a strategic initiative rather than just a finance task. Lab utilization, SG&A efficiency, and reimbursement performance all matter more in the current mix.
• Deploy capital selectively. Fulgent’s strong balance sheet gives it room for acquisitions, internal investment, and share repurchases. Public actions suggest management is trying to balance growth investing with discipline rather than pursuing growth at any price.
• Maintain optionality in therapeutics and biopharma. Fulgent Pharma adds a higher-risk, longer-duration growth vector. As of 2024, this appears strategically important but financially much smaller than the diagnostics platform.

3. What Is the Business Model of Fulgent Genetics?

What customers actually buy

Most customers buy a diagnostic answer, not a physical product. Physicians and hospitals order tests, submit specimens, and receive clinically interpretable reports. In pathology, the service is even more workflow-embedded: tissue is processed, reviewed, and reported as part of patient care. Biopharma customers may buy specialized laboratory support, molecular insights, or capabilities related to precision medicine programs.

Recurring or repeat-driven versus one-time

Fulgent’s revenue is not subscription-based, but much of it is repeat-driven. A hereditary cancer panel for one patient is a one-time order, yet a health system or oncology practice can generate recurring volume every week if Fulgent is embedded in clinical workflow. That is why oncology and pathology matter strategically: they can create denser, more durable specimen flow than purely episodic retail-style testing. By contrast, COVID-19 testing was high volume but much less durable.

How pricing power works

Pricing power is constrained by reimbursement. Diagnostic labs are paid through a mix of Medicare, Medicaid, commercial insurers, managed care contracts, institutional arrangements, and patient payments. Fulgent can influence realized pricing through test mix, evidence generation, payor contracting, billing accuracy, and clinical differentiation, but it does not have unlimited freedom to raise prices. Specialized oncology and genetics assays generally offer better economics than more commoditized testing if clinical utility and reimbursement support are in place.

Why the business mix matters

Business mix is central to understanding Fulgent. A dollar of temporary public-health testing, a dollar of reimbursed hereditary testing, and a dollar of pathology revenue do not have the same persistence, margin profile, or customer stickiness. The company’s strategic pivot is really a mix-improvement story.

What drives gross margin, operating margin, and cash generation

Gross margin is driven by reimbursement yield, reagent and consumable costs, test complexity, lab utilization, automation, and volume density. Operating margin depends heavily on salesforce efficiency, acquired-business integration, and the company’s willingness to keep investing in therapeutics and growth initiatives. Cash generation depends not only on laboratory profitability but also on collections, denial management, and working-capital discipline, because payment often arrives well after test performance.

Revenue model

Fulgent’s core revenue model is fee-for-service diagnostics. It performs tests and pathology services and bills payors, institutions, or other customers. Some revenue streams are contract-based and repeat-driven, but the business is not built around subscriptions or software licenses. Therapeutics and biopharma activities can introduce milestone-like or project-based economics, though those were not the dominant revenue driver through 2024.

4. What Products and/or Services Does Fulgent Genetics Sell?

Fulgent Genetics sells a mix of laboratory testing and related precision-medicine services.

• Genetic testing. This is the company’s legacy foundation. It includes physician-ordered molecular tests across areas such as rare disease, reproductive health, hereditary cancer, and other inherited conditions. The breadth of the menu and the ability to configure assays have historically been part of Fulgent’s differentiation.
• Oncology molecular testing. Through its oncology capabilities and the CSI Laboratories acquisition, Fulgent offers testing relevant to cancer diagnosis, classification, and treatment decision support, including more specialized hematologic and molecular workflows.
• Anatomic pathology. Through Inform Diagnostics, Fulgent participates in tissue-based pathology services. This broadens the company from molecular testing into a larger share of the diagnostic workflow for hospitals and physicians.
• Hematopathology and related cancer diagnostics. These services are strategically important because they deepen relationships with oncologists and pathology customers and can pull through additional molecular testing.
• Biopharma and therapeutics activities. Fulgent Pharma represents a smaller but strategically notable effort in therapeutic development and precision-medicine adjacencies. As of 2024, this appeared far more important to strategic optionality than to current revenue.
• Legacy COVID-19 testing. This became a major revenue driver during the pandemic, but by 2023-2024 it was clearly a declining and non-core part of the long-term thesis.

The offerings that appear most important to current revenue and long-term strategy are core genetic testing, oncology testing, and pathology services. Therapeutics may matter over time, but diagnostics remains the economic center of gravity.

5. What Are the Key Competitors or Peers of Fulgent Genetics?

Fulgent Genetics competes across several adjacent diagnostic categories, so its peer set is broader than a single-product genetics company. The most relevant competitors and peers include:

These companies are not identical substitutes. Quest and Labcorp are broad-scale competitors; NeoGenomics, Guardant, and Tempus are more oncology-centered; Myriad, GeneDx, Natera, and Ambry are closer in certain genetic-testing niches. Fulgent’s challenge is that it competes across several submarkets at once.

6. What Is the Marketing Strategy of Fulgent Genetics?

Fulgent Genetics’ marketing strategy appears to be primarily clinical and account-based rather than consumer-led. The company sells into physician workflows, oncology practices, hospitals, and health systems, so the important marketing levers are clinical education, sales support, reimbursement clarity, turnaround-time credibility, and ease of ordering.

Brand marketing is not the center of the model. Fulgent is not a consumer diagnostics brand in the way some direct-to-consumer testing companies are. Instead, its marketing likely relies on field sales, conference presence, specialty-specific education, key opinion leader engagement, digital ordering tools, and materials that help clinicians understand when and how to use a test. In pathology and oncology, local relationships and trust in report quality can matter as much as formal advertising.

Performance marketing in the classic digital sense appears to be far less important than direct provider outreach and institutional relationship building. That fits the company’s business model: the goal is not broad top-of-funnel awareness, but repeat specimen flow from accounts that can be retained for years.

7. What Are the Key Customer Segments of Fulgent Genetics?

Fulgent Genetics serves several customer groups, with the mix becoming broader after its pathology and oncology acquisitions.

• Specialist physicians. This includes clinicians in genetics, oncology, maternal-fetal medicine, pediatrics, neurology, and related specialties who order molecular and inherited-disease tests.
• Hospitals and health systems. These accounts matter because they can produce recurring specimen volume and often need a broader mix of pathology and molecular services.
• Oncology practices and cancer centers. These customers are especially important to Fulgent’s growth strategy because they can use multiple parts of the company’s offering.
• Pathology users and referring providers. Inform Diagnostics and CSI Laboratories broaden Fulgent’s reach into tissue-based and cancer-related workflows.
• Payors. Insurers are not always the ordering customer, but they are economically critical because reimbursement determines realized revenue.
• Biopharma companies. These are smaller customers in revenue terms than the clinical diagnostics base, but they matter strategically where companion diagnostics, clinical development support, or precision-medicine collaborations are involved.

The company is more diversified than a single-niche genetic testing provider, but it remains concentrated in U.S. healthcare delivery and reimbursement channels. That means provider relationships and payor coverage are more important than broad consumer demand.

8. What Is the Sales Model of Fulgent Genetics?

Fulgent Genetics primarily sells through a direct commercial model. Its salesforce and account teams work with physicians, hospitals, oncology practices, and health systems to win test orders and pathology volume. Specimens are then shipped to the company’s laboratories, processed, interpreted, and reported back through clinical reporting systems and portals.

The sales model has several layers:

• Direct physician and institution sales. This is the core route to market for specialty diagnostics and pathology.
• Workflow integration. Once an account is set up for ordering, specimen logistics, and reporting, the relationship can become relatively sticky.
• Payor-supported selling. Commercial traction is helped when Fulgent has reimbursement coverage, contracted rates, or evidence that reduces friction for ordering physicians.
• Specialty sales for oncology and pathology. These businesses often require a more consultative sale than standard genetic testing because they are embedded in clinical and tissue-processing workflows.

Channel structure matters because Fulgent is not simply shipping kits through retail shelves or online marketplaces. Its growth depends on winning accounts and then increasing share of workflow within those accounts. That creates good opportunities for consultants in salesforce design, account segmentation, and integration of acquired commercial teams.

9. In What Geographies Does Fulgent Genetics Operate?

Fulgent Genetics is primarily a U.S.-focused company. Its economics are tied mainly to U.S. physicians, U.S. hospitals, and the U.S. reimbursement system rather than to a broad multinational diagnostics footprint.

The company is headquartered in Temple City, California, and its historical lab base has been centered in Southern California. Its oncology and pathology expansion added additional U.S. operating hubs through acquired businesses, including CSI Laboratories in Georgia and Inform Diagnostics in Texas. Operationally, that matters more than a simple headquarters map because pathology and oncology services rely on specimen logistics, pathologist workflows, and regionally supported customer relationships.

Commercially, Fulgent serves customers across the United States. Public disclosures through 2024 suggest that international activity exists, but the company remains much more concentrated in the U.S. than globally diversified diagnostics peers. For practical analysis, Fulgent should be understood as a national U.S. specialty diagnostics platform rather than a broad international lab network.

10. Who Are the Owners of Fulgent Genetics?

Fulgent Genetics is a publicly traded company. According to the company’s 2024 proxy materials, founder Ming Hsieh was the largest disclosed beneficial owner. Public institutional filings available in 2024 also showed major asset managers such as Vanguard and BlackRock among notable shareholders. There was no indication in those public materials that the company was controlled by a private-equity sponsor or government owner.

That ownership structure matters because Fulgent still has meaningful founder influence, but it also trades as a public company whose capital allocation decisions are visible to institutional investors.

11. How Is Fulgent Genetics Organized?

Fulgent Genetics is easiest to understand as a platform company with several linked operating businesses. Public reporting through FY2023 emphasized consolidated results, but operationally the company appears to be managed across four practical areas:

• Core genetic testing. The legacy molecular diagnostics business.
• Oncology diagnostics. Including cancer-focused molecular testing and CSI Laboratories.
• Anatomic pathology. Primarily Inform Diagnostics.
• Therapeutics. The Fulgent Pharma effort, which is strategically distinct from the core laboratory business.

Above those businesses sit shared corporate functions such as finance, reimbursement, regulatory compliance, information systems, and capital allocation. This structure is important because Fulgent is no longer a single-line genetic testing company. Its managerial challenge is to preserve specialization in each business while still creating cross-business value through shared technology, commercial coordination, and back-office leverage.

12. How Does Fulgent Genetics Operate?

On a day-to-day basis, Fulgent Genetics operates as a specimen-driven diagnostics company. The workflow begins when a physician, practice, or institution orders a test or pathology service and sends a specimen to one of Fulgent’s laboratories. The sample is accessioned, matched to the order, and routed through the relevant workflow.

For molecular testing, that generally means sample preparation, sequencing or other laboratory analysis, bioinformatics processing, variant interpretation, medical review, and report generation. For pathology, the workflow includes specimen handling, slide preparation, histology, pathologist review, ancillary testing where needed, and final reporting. In oncology settings, multiple disciplines may be combined to deliver a clinically useful result.

The company also has to manage functions that are economically as important as the lab itself: specimen logistics, chain-of-custody controls, test utilization management, reimbursement coding, billing, collections, customer service, and regulatory compliance. In other words, Fulgent does not simply run machines; it runs an end-to-end clinical operations system in which accuracy, turnaround time, and reimbursement yield all affect value creation.

13. What Are the Growth Opportunities for Fulgent Genetics?

Fulgent Genetics has several plausible growth opportunities based on public evidence.

• Cross-selling oncology, pathology, and molecular services. This is probably the clearest strategic opportunity. If Fulgent can combine the capabilities of its acquired businesses into a more integrated offering, account value and retention could improve.
• Deeper penetration of hospitals and health systems. Larger institutional customers can produce recurring specimen flow and support broader service adoption than one-off physician ordering.
• Expansion in reimbursed specialty testing. Rare disease, reproductive health, hereditary cancer, and precision oncology remain attractive areas if the company can continue to support clinical utility and reimbursement.
• Selective M&A. Fulgent’s cash resources give it optionality to add capabilities, geography, or customer access through acquisitions.
• Biopharma and companion-diagnostics adjacencies. These may not be the core economic engine today, but they can create higher-value relationships and help differentiate the platform.
• Operational improvement. Not all growth must come from new tests. Better reimbursement realization, lower denials, stronger commercial productivity, and smoother acquired-business integration can all improve economic output from the existing revenue base.

The main constraints are also clear: reimbursement pressure, strong competition, the difficulty of integrating pathology and molecular workflows, and the risk that therapeutics investment consumes capital without near-term return. Fulgent has opportunities, but execution quality matters more now than raw test capacity.

14. What Is the History of Fulgent Genetics?

Fulgent Genetics was founded in 2011. The company initially built its identity around technology-enabled genetic testing and went public in 2016, giving it access to public capital as it expanded its menu and laboratory footprint.

The company became much more widely known during the COVID-19 pandemic, when testing demand surged and transformed its financial profile. That period generated substantial revenue and cash, but it also created a strategic reset once pandemic testing normalized.

In the early 2020s, Fulgent used that financial capacity to broaden beyond its original niche. It acquired CSI Laboratories in 2021, adding cancer diagnostics and hematopathology capabilities. In 2022 it acquired Inform Diagnostics, a much larger step into anatomic pathology. It also invested in a therapeutics effort under Fulgent Pharma.

By 2023 and into 2024, the company’s history was no longer just a genetics story or a COVID story. It had become a post-pandemic portfolio reshaping story: using a strong balance sheet and acquired capabilities to build a more diversified precision diagnostics platform.

15. What Are the Key Suppliers to Fulgent Genetics?

Suppliers matter to Fulgent Genetics even though the company does not publicly disclose a long, named supplier roster in recent annual reporting. The critical supplier categories are clear.

• Sequencing instruments and laboratory equipment. Fulgent depends on specialized molecular diagnostics hardware and the service support behind it.
• Reagents, consumables, and pathology materials. These include the inputs required for sequencing workflows, tissue processing, slide preparation, and related lab work.
• Specimen collection and logistics partners. Collection kits, shipping materials, and courier networks are essential because a specimen-based diagnostics model fails if samples do not move reliably and compliantly.
• Laboratory software and infrastructure vendors. Laboratory information systems, workflow tools, storage, and other technology vendors support order management and report delivery.

Supplier structure matters strategically because Fulgent operates in reimbursed markets where pricing is constrained. That means input reliability, consumable cost, and equipment uptime can have an outsized effect on margin and turnaround time.

16. How Does the Supply Chain of Fulgent Genetics Function?

Fulgent Genetics’ supply chain is best understood as a specimen-and-reagent supply chain rather than a traditional finished-goods chain. On the inbound side, the company needs a steady flow of collection kits, consumables, pathology materials, and laboratory reagents. It also needs reliable service and maintenance for specialized instruments.

The operating chain then depends on specimen movement: samples are collected, packaged, shipped, received, accessioned, and routed through the correct laboratory workflow. For pathology and oncology, chain of custody and processing discipline are especially important because tissue handling errors can delay or compromise diagnosis.

Inventory management matters because reagents can be costly and some have limited shelf life. Transportation and specimen integrity matter because diagnostic value depends on usable samples arriving on time. This is one reason turnaround time can be a real competitive lever: it reflects both laboratory productivity and supply-chain reliability.

17. What Is the Technology Strategy of Fulgent Genetics?

Technology has long been central to Fulgent Genetics’ strategy. The company has consistently described itself as a technology-enabled diagnostics platform rather than just a laboratory with a fixed test menu. Its core technology strengths appear to include test design flexibility, bioinformatics, data interpretation, and software that supports ordering and reporting.

There are two layers to this strategy. The first is internal enablement: automation, workflow management, and bioinformatics help the company process tests accurately and efficiently. The second is customer-facing utility: broad menu configurability, digital ordering, and interpretable reporting can make the platform more useful to physicians and institutions.

Technology also matters more now that Fulgent spans multiple diagnostic modalities. The strategic challenge is not only running sequencing pipelines well, but also connecting molecular data, pathology workflows, and customer reporting in a way that feels integrated rather than pieced together through acquisitions.

18. What Is the R&D Strategy of Fulgent Genetics?

Fulgent Genetics’ research and development strategy appears to be applied and commercially oriented. In diagnostics, R&D means developing and validating new assays, updating panels as scientific knowledge evolves, improving bioinformatics, and generating the evidence needed for clinical adoption and reimbursement.

That kind of R&D is different from blue-sky pharmaceutical research. It is closer to assay innovation, workflow improvement, and menu expansion. For Fulgent, this is strategically important because the company competes in markets where new clinical use cases, new variants, and new oncology markers can change the attractiveness of a test offering.

The therapeutics business adds a more traditional biopharma-style R&D layer. That could create upside over time, but it also raises execution risk and increases the range of capabilities management has to oversee. As of 2024, diagnostics R&D looked like the more immediate and economically relevant part of the company’s innovation strategy.

19. What Is the Finance Strategy of Fulgent Genetics?

Fulgent Genetics’ finance strategy has been unusually important because the company emerged from the COVID-19 period with a strong balance sheet relative to its current revenue base. Public filings through FY2023 showed substantial liquidity and a lightly levered financial profile, giving management more strategic flexibility than many small and mid-cap diagnostics peers.

That flexibility has supported three broad priorities:

• Capability-building acquisitions. The purchases of CSI Laboratories and Inform Diagnostics were funded from a position of financial strength.
• Organic reinvestment. Fulgent continues to fund diagnostics growth initiatives and a therapeutics effort despite a much lower revenue base than at the height of pandemic testing.
• Share repurchases. The company has also used buybacks as part of capital allocation rather than relying on dividends.

The key finance challenge now is not raising capital; it is deploying capital well. That means balancing growth investments against profitability, keeping a close eye on reimbursement collections and working capital, and avoiding overextension in businesses that are strategically interesting but not yet economically proven.

20. What Major Acquisitions Has Fulgent Genetics Made?

Acquisitions have played an important role in Fulgent Genetics’ evolution from a narrower genetic testing company into a broader precision diagnostics platform.

• CSI Laboratories (closed in 2021). This acquisition added cancer diagnostics and specialized hematopathology capabilities. Strategically, it helped Fulgent move deeper into oncology workflows and broaden beyond inherited-disease testing.
• Inform Diagnostics (closed in 2022). This was a major step into anatomic pathology and materially expanded Fulgent’s scale, customer access, and service breadth. It also changed the company’s operating profile by adding a business with different workflow, staffing, and commercial dynamics than stand-alone molecular testing.

These deals suggest that Fulgent uses M&A primarily for capability building and portfolio reshaping rather than as a pure roll-up strategy. The real strategic question is no longer whether the assets were acquired, but how effectively they are integrated commercially, operationally, and technologically.

21. How Companies Like Fulgent Genetics Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. Companies like Fulgent Genetics use Umbrex when they need high-caliber strategy and execution support without hiring a full consulting team with all the overhead. For a company navigating a post-COVID portfolio reset, oncology and pathology integration, reimbursement complexity, and capital deployment choices, that model can be especially useful.

Representative projects Umbrex consultants could support for a company like Fulgent Genetics include:

• Design a growth strategy for integrating core genetics, oncology testing, and anatomic pathology into a more coherent customer offering.
• Run a post-acquisition integration program for pathology and oncology businesses, including shared services, organization design, and synergy tracking.
• Redesign the commercial model and territory structure for hospitals, oncology practices, and health-system accounts.
• Improve reimbursement economics through payer strategy, denial management, billing process redesign, and test-prioritization analytics.
• Reduce laboratory turnaround time and improve throughput through operations diagnostics, workflow redesign, and productivity benchmarking.
• Strengthen specimen logistics and reagent planning through a supply-chain resilience and vendor-risk review.
• Build a portfolio strategy and capital allocation framework across diagnostics, pathology, oncology, therapeutics, buybacks, and M&A.
• Support diligence on acquisition targets in specialty diagnostics, pathology, or precision oncology.
• Develop a technology and data roadmap for laboratory systems, reporting workflows, automation, and bioinformatics operating priorities.
• Identify SG&A productivity opportunities and design a margin-improvement program suited to a lower but more durable post-pandemic revenue base.